Absence of Nitrate Tolerance After Long-term Treatment with Ramipril: an Endothelium-dependent Mechanism
Overview
Affiliations
To determine whether nitrate tolerance is attenuated on aortas isolated from rats treated in the long term with an angiotensin-converting enzyme (ACE) inhibitor, five groups of rats were studied in parallel. Group 1 received ramipril, 1 mg/ kg/day, p.o., for 6 weeks; group 2 received ramipril at the same dose for 4 weeks, and the last 2 weeks, a cotreatment with ramipril plus HOE 140 (a bradykinin B2 antagonist, 500 microg/ kg/day, s.c. injections); group 3 received losartan, 2 mg/kg/day, p.o., for 6 weeks; group 4 received losartan at the same dose, and the last 2 weeks, a cotreatment with losartan plus HOE 140; and group 5 served as control. Rings of thoracic aorta from these groups were studied in organ baths. After nitroglycerin preincubation (10 microM for 30 min) in vitro, the dose-response curves to nitroglycerin were significantly shifted to the right in the control group but not in group 1. This protective effect was partially present in group 3; it was completely abolished in groups 2 and 4. In groups 1 and 3, it also was abolished after nitric oxide synthase (cNOS) inhibition (L-NMMA incubation) or removal of the endothelium. Superoxide anion accumulation (assessed by lucigenin chemiluminescence) was increased by nitroglycerin incubation in the control group but not in groups 1 and 3. After in vivo exposure to nitroglycerin (50 mg/kg subcutaneously twice daily for 4 days), this protection against nitrate tolerance also was observed in groups 1 and 3. Thus long-term ACE inhibition prevents nitrate tolerance by an endothelium-dependent mechanism involving mainly an enhanced NO availability via B2-kinin receptor. This effect on the cNOS pathway seems to attenuate the superoxide anion accumulation induced by nitroglycerin exposure (probably via a downregulation of oxidative enzyme).
Munzel T, Daiber A Antioxid Redox Signal. 2023; 38(13-15):1001-1021.
PMID: 36719770 PMC: 10171967. DOI: 10.1089/ars.2023.0006.
Daiber A, Munzel T Antioxid Redox Signal. 2015; 23(11):899-942.
PMID: 26261901 PMC: 4752190. DOI: 10.1089/ars.2015.6376.
Oelze M, Schuhmacher S, Daiber A Exp Diabetes Res. 2011; 2010:213176.
PMID: 21234399 PMC: 3014692. DOI: 10.1155/2010/213176.
Watanabe Y, Kusama N, Itoh T Br J Pharmacol. 2007; 153(1):132-9.
PMID: 17965730 PMC: 2199382. DOI: 10.1038/sj.bjp.0707562.
Otto A, Fontaine J, Tschirhart E, Fontaine D, Berkenboom G Br J Pharmacol. 2006; 148(4):544-52.
PMID: 16633368 PMC: 1751785. DOI: 10.1038/sj.bjp.0706738.